Insider Buying: Opko Health Inc. (NASDAQ:OPK) CEO Buys 50,000 Shares of Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The stock was purchased at an average cost of $2.16 per share, with a total value of $108,000.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $6,628,934.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, July 16th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.12 per share, with a total value of $106,000.00.
  • On Monday, July 8th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.23 per share, with a total value of $223,000.00.
  • On Tuesday, July 2nd, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were bought at an average cost of $2.42 per share, with a total value of $121,000.00.
  • On Tuesday, June 25th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The shares were bought at an average cost of $2.01 per share, with a total value of $201,000.00.
  • On Thursday, June 20th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were bought at an average cost of $2.04 per share, with a total value of $102,000.00.
  • On Tuesday, June 18th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were bought at an average cost of $2.02 per share, with a total value of $101,000.00.
  • On Thursday, June 13th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were bought at an average cost of $1.92 per share, with a total value of $96,000.00.
  • On Tuesday, June 11th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were bought at an average cost of $1.87 per share, with a total value of $93,500.00.
  • On Friday, June 7th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The shares were bought at an average cost of $1.87 per share, with a total value of $93,500.00.
  • On Wednesday, June 5th, Phillip Md Et Al Frost acquired 150,000 shares of Opko Health stock. The shares were bought at an average cost of $1.92 per share, with a total value of $288,000.00.

OPK stock opened at $2.11 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.99 and a current ratio of 1.10. The stock’s fifty day moving average is $2.07. Opko Health Inc. has a one year low of $1.73 and a one year high of $6.30. The company has a market capitalization of $1.32 billion, a PE ratio of -8.44 and a beta of 2.14.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.08). Opko Health had a negative return on equity of 9.86% and a negative net margin of 19.92%. The company had revenue of $222.50 million for the quarter, compared to the consensus estimate of $241.27 million. During the same period last year, the firm earned ($0.08) earnings per share. The company’s revenue for the quarter was down 12.7% compared to the same quarter last year. Research analysts expect that Opko Health Inc. will post -0.42 EPS for the current fiscal year.

A number of equities analysts have commented on OPK shares. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research cut shares of German American Bancorp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and an average target price of $9.25.

A number of hedge funds have recently added to or reduced their stakes in OPK. Piedmont Investment Advisors Inc. bought a new stake in shares of Opko Health in the first quarter valued at about $27,000. Meeder Asset Management Inc. boosted its position in shares of Opko Health by 58.7% in the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 4,846 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in shares of Opko Health in the first quarter valued at about $39,000. B. Riley Wealth Management Inc. bought a new stake in shares of Opko Health in the first quarter valued at about $39,000. Finally, Two Sigma Advisers LP bought a new stake in shares of Opko Health in the fourth quarter valued at about $49,000. 25.35% of the stock is owned by hedge funds and other institutional investors.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: The Discount Rate – What You Need to Know

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.